BioNote

BioNote FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of BioNote (377740.KS) as of Oct 18, 2026 is -6.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 85.84 % — a change of -108.14% (lower).

FCF Conversion

-6.98 %

YoY

-108.14%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of BioNote is 2025 -6.98 % . FCF Conversion Rate (FCF/EBITDA) of BioNote was 2024 85.84 % . It decreases by -108.14% lower compared to the previous year.

The BioNote FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
40.38 KRW
Jan 1, 2020
40.36 KRW
Jan 1, 2021
71.81 KRW
Jan 1, 2022
67.13 KRW
Jan 1, 2023
42.62 KRW
Jan 1, 2024
85.84 KRW
Jan 1, 2025
-6.98 KRW
The BioNote FCF Conversion history
YEARFCF ConversionYoY
-6.98 %-108.14%
85.84 %+101.40%
42.62 %-36.51%
67.13 %-6.52%
71.81 %+77.91%
40.36 %-0.04%
40.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNote Stock analysis

What does BioNote do? BioNote Inc., headquartered in Hwaseong, South Korea, operates in the Health Care sector, specifically within Biotechnology. The company develops and manufactures rapid diagnostic kits for humans and animals, including immunochemical and fluorescence-based diagnostic products. It also produces raw materials such as antigens, antibodies, and enzymes, along with semi-finished products for diagnostic use. Listed on December 22, 2022, BioNote focuses on veterinary and human diagnostic solutions. BioNote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNote stock

FCF Conversion Rate (FCF/EBITDA) of BioNote is -6.98 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of BioNote changed from 85.84 % to -6.98 %, representing a -108.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) BioNote since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s BioNote with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioNote

All Key Metrics — BioNote